Advances in therapeutic targeting of immune checkpoints receptors within the CD96-TIGIT axis: clinical implications and future perspectives.
Pooya FarhangniaMahzad AkbarpourMahboubeh YazdanifarAmir Reza ArefAli-Akbar DelbandiNima RezaeiPublished in: Expert review of clinical immunology (2022)
CD96-TIGIT axis regulates anti-tumor immune responses. Thus, the receptors within this axis are the potential candidates for cancer immunotherapy. Combining the inhibition of CD96-TIGIT with anti-PD-1/PD-L1 mAbs and chemotherapy drugs has shown relatively effective results in the context of preclinical studies and tumor models.